Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]
Discontinued
Reference number: GID-TA10109
Following on from information provided to NICE by the company in May 2018, the appraisal of Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.